DotBio Secures Tens of Millions in Pre-A Funding to Advance Modular Multispecific Antibody Platform for Oncology

● DotBio, a biotechnology company focused on the research and development of tumor immunotherapies, has raised new funding to accelerate the development of its multifunctional antibodies.

● This round of financing was led by Proxima Ventures and Gaorong Capital, with participation from the AIM-HI Accelerator Fund, Xiading Investment, and Baotai Biomedical.

Today, DotBio, a biopharmaceutical company dedicated to delivering more effective therapies to patients through innovative antibody technologies, announced the completion of its Pre-A financing round, raising tens of millions of yuan. The round was led by Proxima Ventures and Gaorong Capital, with participation from investors including the AIM-HI Accelerator Fund.

The financing proceeds will be used to conduct preclinical studies, including animal efficacy studies and chemistry, manufacturing, and controls (CMC) research, to help validate the potential of candidate therapeutics for advancement into clinical stages. Additionally, the funds will accelerate the expansion and automation of DotBio’s proprietary modular platform, DotBody, which is designed to screen intracellular and extracellular tumor immunotherapy targets from thousands of multifunctional antibody prototypes, identifying those suitable for developing next-generation clinical candidates.

 Dot Biotech Innovatively Applies Modular Design Concepts to the Antibody Field

Proxima Capital Partners, the lead investor in this round, is headquartered in Shanghai and focuses on investing in next-generation medical technology companies. Mr. Song Haolin, Partner at Proxima Capital Partners, will serve as a member of the Board of Directors of Duote Bio; he is also an experienced biotechnology entrepreneur. Gaorong Capital specializes in early- and growth-stage investments in new technologies, new consumer sectors, and healthcare. Dr. Le Beilin, Executive Director at Gaorong Capital, will serve as a board observer for Duote Bio. The AIM-HI Accelerator Fund is a U.S.-headquartered global non-profit organization dedicated to advancing technological and therapeutic breakthroughs in oncology. Its Co-founder and CEO, Dr. Ba Sujuan, will also serve as a strategic advisor to Duote Bio.

Ignacio Asial, CEO of Duote Bio“With this Pre-A financing round, we are delighted to have secured support from a leading life sciences investment institution, which will enable us to accelerate the development of our portfolio of multifunctional antibodies for treating various cancers and improving patients’ quality of life. We are making significant progress in the development of intracellular antibody therapies, with related findings published in Nature Communications in 2022. This funding round accelerates our march toward the goal of fundamentally transforming approaches to intracellular tumor targeting. As collaborative projects are poised to enter clinical trials in the near term, they will further mitigate risks associated with humanized antibodies, thereby supporting the development of more advanced therapeutic modalities. We also warmly welcome Mr. Haolin Song to our Board of Directors. His extensive experience in founding, managing, and financing international biotechnology companies will be immensely valuable as we enter our next phase of growth.”

Mr. Song Haolin, Partner at Proxima Ventures“Globally, novel multi-target therapeutic approaches are gaining momentum and hold promise for expanding the frontiers of treatment. We are delighted to collaborate with Duote Bio. Duote Bio employs a data-driven approach to compare thousands of prototype molecules to identify multispecific antibodies and mitigate their risks, which is a highly forward-looking strategy. I am excited about Duote Bio’s modular technology platform and believe it will bring unprecedented possibilities to patients worldwide by accelerating the design of potential antibody prototypes targeting disease factors both inside and outside cells. I look forward to jointly supporting Duote Bio in its mission to bring more effective oncology therapies to patients more rapidly.”

Le Beilin, Executive Director at Gaorong Capitalstated, “DuoTe Bio’s humanized nanobody technology platform possesses unique and differentiated features, with the potential to bring about transformative changes in the field of multifunctional antibodies. Its previous collaborations with CStone Pharmaceuticals, Junshi Biosciences, and Linkage Biologics have already demonstrated the company’s value. Notably, the pipeline developed in partnership between DuoTe Bio and Junshi Biosciences has submitted an Investigational New Drug (IND) application for regulatory approval. We look forward to witnessing further development of the company and accelerated progress in its pipeline in the future.”

DotBio is a highly innovative biopharmaceutical company dedicated to delivering more effective therapies to patients through next-generation antibody technologies. DotBio employs innovative therapeutic approaches to achieve optimal efficacy by rapidly designing multifunctional antibody prototypes to identify candidates with synergistic activity, optimal structures, and unique mechanisms of action. The company’s methodologies leverage its modular DotBody technology platform, Colony Filtration (CoFi), High-Temperature Colony Filtration (Hot-CoFi), high-throughput miniaturized assays, and data analytics to produce unique therapeutic molecules targeting both intracellular and extracellular disease factors. As a platform-based enterprise, DotBio is building a diverse portfolio of targeted DotBody modules and multiple preclinical assets in the field of tumor immunology.